Irma Veberic – General Manager, Roche Hungary
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
Address: Budaörs 2040 Edison u. 1. Hungary,Hungary
Tel: +36-23-446-871
Web: http://www.roche-diagnostics.hu/portal/dia/rolunk
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management.
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
The managing director of Wörwag Pharma Hungary, Dr. Éva Kádár depicts the company’s impressive evolution, highlighting the expansive network of neuropathy centers that they’ve helped establish all over Hungary and…
Soneas MD Jozsef Repasi discusses the shift back towards Central and Eastern Europe for contract manufacturing services, the company’s growth since separating from Ubichem, and his ambitions for Soneas to…
AmCham Hungary, one of the largest American Chambers of Commerce in Central and Eastern Europe, discusses their advocacy efforts, particularly highlighting the chamber’s recently established Healthy Nation Policy Task Force…
Hungary has long boasted a vibrant, skilled pharmaceutical industry that continues to attract the interest of local and multinational entities alike. This fact was highlighted today at the celebration of GlaxoSmithKline’s…
The managing director of CSL Behring Hungary, Attila Lukács, discusses the company’s recent establishment in Hungary, the strategic benefits the country offers, as well as his experience starting an affiliate…
Meda Pharma Hungary GM Dr. Laszlo Gaspar describes how the strategic shift from Rx to OTC has allowed the company to experience year-on-year growth over the last eight years and…
The country manager of Berlin-Chemie / A. Menarini Hungary, Dr. Peter Olah, explains the impact of a more targeted sales force in driving the company in the last three years,…
Agnès Ducrot and Miklos Maróthy of CCI France Hongrie discuss their advocacy efforts in Hungary and the history of French investment in the country. They also discuss the challenges and opportunities…
The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much…
Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy,…
The managing director of Janssen Hungary, Andreas Woitossek, depicts the valuable role of real-world evidence in enabling the affiliate’s consistent double-digit growth over the last four years, while highlighting the…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
See our Cookie Privacy Policy Here